These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26916563)

  • 1. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.
    Al-Ali HK; Stalbovskaya V; Gopalakrishna P; Perez-Ronco J; Foltz L
    Leuk Lymphoma; 2016 Oct; 57(10):2464-7. PubMed ID: 26916563
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
    Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
    Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
    Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
    Gupta V; Harrison C; Hexner EO; Al-Ali HK; Foltz L; Montgomery M; Sun W; Gopalakrishna P; Kantarjian H; Verstovsek S
    Haematologica; 2016 Dec; 101(12):e482-e484. PubMed ID: 27587385
    [No Abstract]   [Full Text] [Related]  

  • 5. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
    Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R
    Leuk Lymphoma; 2024 Jul; 65(7):965-977. PubMed ID: 38501751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does ruxolitinib prolong the survival of patients with myelofibrosis?
    Cervantes F; Pereira A
    Blood; 2017 Feb; 129(7):832-837. PubMed ID: 28031182
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.
    Crisà E; Cilloni D; Elli EM; Martinelli V; Palumbo GA; Pugliese N; Beggiato E; Frairia C; Cerrano M; Lanzarone G; Marchetti M; Mezzabotta M; Boccadoro M; Ferrero D
    Br J Haematol; 2018 Sep; 182(5):701-704. PubMed ID: 29984826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
    Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
    Br J Haematol; 2013 May; 161(4):508-16. PubMed ID: 23480528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre.
    Iurlo A; Cattaneo D; Giunta M; Gianelli U; Consonni D; Fraquelli M; Orofino N; Bucelli C; Bianchi P; Augello C; Bosari S; Colombo M; Cortelezzi A
    Br J Haematol; 2015 Sep; 170(6):890-2. PubMed ID: 25753891
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
    Komatsu N; Kirito K; Shimoda K; Ishikawa T; Ohishi K; Ohyashiki K; Takahashi N; Okada H; Amagasaki T; Yonezu T; Akashi K
    Int J Hematol; 2017 Mar; 105(3):309-317. PubMed ID: 27832516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
    J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
    Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
    Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
    Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
    J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
    Deisseroth A; Kaminskas E; Grillo J; Chen W; Saber H; Lu HL; Rothmann MD; Brar S; Wang J; Garnett C; Bullock J; Burke LB; Rahman A; Sridhara R; Farrell A; Pazdur R
    Clin Cancer Res; 2012 Jun; 18(12):3212-7. PubMed ID: 22544377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
    Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P; Gupta V; Tannir B; Ronco JP; Ghosh J; Martino B; Vannucchi AM
    Haematologica; 2016 Sep; 101(9):1065-73. PubMed ID: 27247324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
    Mazza P; Specchia G; Di Renzo N; Cascavilla N; Tarantini G; Capalbo SF; Urbano T; Albano F; Giovannni R; Falcone AP; Santeramo MT; Spinosa G; Pisconti S
    Leuk Lymphoma; 2017 Jan; 58(1):138-144. PubMed ID: 27263544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
    Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
    Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.